SHANGHAI BIO-HEART BIOLOGICAL TECHNOLOGY CO., LTD. Shanghai Bio-heart Biological Technology Co., Ltd. Share Price
Equities
2185
CNE100004JH3
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.02 HKD | +3.59% |
|
+6.32% | -40.94% |
| Sales 2023 | - | Sales 2024 * | 21M 2.9M 22.69M 232M | Capitalization | 455M 62.82M 492M 5.03B |
|---|---|---|---|---|---|
| Net income 2023 | -176M -24.29M -190M -1.95B | Net income 2024 * | -59M -8.14M -63.74M -652M | EV / Sales 2023 | - |
| Net cash position 2023 * | - 0 0 0 | Net cash position 2024 * | - 0 0 0 | EV / Sales 2024 * | 21.7 x |
| P/E ratio 2023 |
-4.32
x | P/E ratio 2024 * |
-7.79
x | Employees | 32 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 47.42% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.59% | ||
| 1 week | +6.32% | ||
| Current month | -11.40% | ||
| 1 month | -10.62% | ||
| 3 months | -30.34% | ||
| 6 months | -22.31% | ||
| Current year | -40.94% |
1 week
1.79
2.02
1 month
1.792.38
Current year
1.793.70
1 year
1.796.77
3 years
1.7975.55
5 years
1.7975.55
10 years
1.7975.55
| Managers | Title | Age | Since |
|---|---|---|---|
Li Wang
CEO | Chief Executive Officer | 55 | 17/07/14 |
Tao Cai
CHM | Chairman | 38 | 30/06/14 |
Yun Qing Wang
DFI | Director of Finance/CFO | 40 | 03/09/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Wang
CEO | Chief Executive Officer | 55 | 17/07/14 |
Sheung Wai Chan
BRD | Director/Board Member | 70 | 23/11/20 |
Xu Bo Lu
BRD | Director/Board Member | 44 | 23/11/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2.02 | +3.59% | 47,900 |
| 25/04/24 | 1.95 | +4.84% | 51,200 |
| 24/04/24 | 1.86 | -3.12% | 124,500 |
| 23/04/24 | 1.92 | +3.23% | 25,800 |
| 22/04/24 | 1.86 | -2.11% | 51,300 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Shanghai Bio-Heart Biological Technology Co Ltd is a China-based company mainly engaged in interventional instruments. The Company's main businesses are the development and production of interventional cardiovascular devices. The Company's main products include fully bioresorbable scaffolds (BRS) and renal denervation (RDN). The Company's products are mainly used to meet medical needs for the treatment of coronary, peripheral artery disease and hypertension.
Calendar
01/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.02
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.94% | 62.81M | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +25.15% | 4.99B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B |
- Stock Market
- Equities
- 2185 Stock
